Morepen Laboratories (NSE:MOREPENLAB) submitted a newspaper publication filing to NSE on 26 August 2026, confirming publication of notices relating to its 41st Annual General Meeting, a dividend declaration, and an associated record date, as required under SEBI Listing Obligations and Disclosure Requirements Regulations 30 and 47.
Key Highlights
- The company published AGM, dividend, and record date notices in Financial Express (English) and Jansatta (Hindi) on 26 August 2026.
- The filing was submitted in compliance with Regulations 30 and 47 of the SEBI (LODR) Regulations, 2015, as amended.
- The notices relate to Morepen Laboratories' 41st Annual General Meeting, indicating the company was incorporated in or around 1984.
- Copies of the newspaper publications are available on the company's official investor relations portal as disclosed in the filing.
About the Company
Morepen Laboratories (NSE:MOREPENLAB) is a Baddi, Himachal Pradesh-based pharmaceutical manufacturer engaged in active pharmaceutical ingredients (APIs), formulations, and home diagnostics under brands including Dr. Morepen. The company operates manufacturing plants in Baddi and maintains its corporate office in Gurugram, Haryana. It is listed on both NSE and BSE (Scrip Code: 500288) and operates within the pharma and healthcare sector.
Announcement in Detail
On 26 August 2026, Morepen Laboratories filed copies of newspaper publications with NSE and BSE confirming that notices pertaining to its 41st Annual General Meeting, a dividend, and the related record date were published in two widely circulated newspapers: Financial Express in English and Jansatta in Hindi. The filing was signed by Company Secretary Vipul Kumar Srivastava and submitted under SEBI LODR Regulations 30 and 47.
The announcement confirms the company fulfilled its statutory obligation to publicise AGM and corporate action details through print media. The filing does not specify the quantum of dividend per share, the exact AGM date, or the numerical record date within the text of the regulatory submission itself; those details are contained in the attached newspaper advertisement copies referenced in the filing.
Impact on Investors
Investors will note that the filing establishes a record date in connection with a dividend, meaning shareholders on record as of that date will be eligible to receive the declared dividend. The filing shows that the specific dividend amount per share and the precise record date are disclosed within the newspaper advertisement attachments referenced by the company, and shareholders should refer to the official exchange filing for those confirmed figures.
The disclosed terms indicate this is a compliance-driven disclosure confirming publication of AGM and dividend notices rather than announcing a new or unexpected corporate event. Shareholders will observe that attending or participating in the 41st AGM, either in person or through proxy or electronic voting, will require reference to the formal AGM notice for venue, date, and agenda details.
Sector / Market Context
India's pharmaceutical sector continues to be a significant contributor to the domestic economy, with the industry body FICCI estimating the Indian pharma market at over USD 50 billion. The API segment, in which Morepen Laboratories is an established participant, has received focused policy attention under the government's Production Linked Incentive scheme for pharmaceuticals, which aims to strengthen domestic API manufacturing capacity and reduce import dependence. Annual general meetings in the pharma sector during this period typically address dividend distributions, audited annual results, and forward-looking compliance matters under SEBI's evolving governance framework for listed entities.